Fully quantitative bulk and comprehensive
single cell proteomics are now both available on the IsoSpark
platform
EMERYVILLE, Calif., Sept. 15,
2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL),
the functional cell biology company, today announced the launch of
Meteor™ chips on the IsoSpark™ platform, providing a
significant advancement in high throughput, quantitative, fully
automated, multiplexed bulk proteomics. ™
The Meteor chip solution enables researchers to conduct high
throughput proteomic analysis with unmatched efficiency. Leveraging
state-of-the-art capabilities, this innovative solution offers the
following key features:
- Automated data analysis and ease-of-use: Researchers can
go from sample to answer in an automated and streamlined method and
generate ready-to-publish data without requirement of a
bioinformatics skillset. With less than 30 minutes hands-on time
and just one-pipette action to load each sample, the Meteor chip
eliminates the need for the laborious proteomics workflow of
traditional proteomic methods.
- High throughput: A single full run (4 chips)
accommodates 80 sample wells in triplicate. The Meteor chip will be
launched with an initial 10-plex panel, capable of generating a
remarkable 2400 data points per run. By enabling high throughput
analysis, minimal sample volume, and automated data analysis,
researchers can now accelerate their studies and unlock new
discoveries in a wide range of applications, including oncology,
drug development, and personalized medicine.
- Quantitative analysis: Each run
incorporates recombinant standards run in triplicate, enabling
quantitative analysis per chip on-site. Researchers gain a
comprehensive understanding of the proteomic landscape, enabling
deeper insights into cellular functions.
Dr. Sarah J. Parker, co-director
of Proteomics and Metabolomics at the Cedars Sinai Smidt Heart
Institute provided the following testimonial after running samples
on the Meteor chip: "As a core facility, we have experience with
other ELISA platform workflows that require sample preparation and
a lot of manual steps. In comparison, the Meteor chip is extremely
easy to use since it streamlines sample preparation and automates
many of the things we do in the lab. The 10-plex available from the
Meteor chip matches what we typically perform on other platforms
while the lower sample volume gives us more leeway with our use
cases. Finally, we like how the data analysis is fully automated in
IsoSpeak® software which gives us easy-to-access visualizations and
insights into our samples."
PhenomeX will showcase Meteor at the upcoming BioProcess
International 2023 meeting, held from September 18-21 at the Boston Convention and
Exhibition Center. Visitors can explore the transformative
capabilities of this advanced technology firsthand at Booth #1152.
PhenomeX representatives will be available to provide
demonstrations and discuss how the Meteor solution can
revolutionize proteomics research and accelerate scientific
advancements.
For more information about the Meteor solution on the IsoSpark
platform, please visit the PhenomeX website at
https://phenomex.com/products/chips/meteor/.
About PhenomeX
PhenomeX is empowering scientists to leverage the full potential of
each cell and drive the next era of functional cell biology that
will advance human health. We enable scientists to reveal the most
complete insights on cell function and obtain a full view of the
behavior of each cell. Our unique suite of proven high-throughput
tools and services offer unparalleled resolution and speed,
accelerating the insights that are key to advancing discoveries
that can profoundly improve the prevention and treatment of
disease. Our award-winning platforms are used by researchers across
the globe, including those at the top 15 global pharmaceutical
companies and approximately 85% of leading U.S. comprehensive
cancer centers.
PhenomeX has no affiliation with Phenomenex, Inc. PhenomeX will
be changing its name. All inquiries regarding Phenomenex, Inc.
and/or its products should be directed to info@phenomenex.com.
Forward-Looking Statements
To the extent that
statements contained in this press release are not descriptions of
historical facts regarding PhenomeX or its products, they are
forward-looking statements reflecting the current beliefs and
expectations of management. Such forward-looking statements involve
substantial known and unknown risks and uncertainties that relate
to future events, and actual results and product performance could
differ significantly from those expressed or implied by the
forward-looking statements. PhenomeX undertakes no obligation to
update or revise any forward-looking statements. For a further
description of the risks and uncertainties relating to the
Company's growth and continual evolution see the statements in the
"Risk Factors" sections, and elsewhere, in our filings with the
U.S. Securities and Exchange Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/phenomex-unveils-meteor-chips-for-quantitative-bulk-analysis-on-the-isospark-platform-to-revolutionize-high-throughput-multiplexed-hands-free-proteomics-301929170.html
SOURCE PhenomeX